Business
Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025)
MONTPELLIER, France, November 13, 2025--Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell’s (Paris:MEDCL) corporate overview during a fireside chat at the Jefferies London Global Healthcare Conference on Tuesday, November 18, 2025, at 4:00 p.m. GMT (5:00 p.m. CET).
About this update from Medincell Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/e44a3a0a1ea53bdd059dfb682b91a7b5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Xl6wUCtUigeX2HP4xWO5ZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e44a3a0a1ea53bdd059dfb682b91a7b5","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/kx0GXNbLiEUy02jRQGQw1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e44a3a0a1ea53bdd059dfb682b91a7b5","width":1200,"height":200}},"lazy":false},{"type":"text","content":"MONTPELLIER, France, November 13, 2025--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell’s (Paris:MEDCL) corporate overview during a fireside chat at the Jefferies London Global Healthcare Conference on Tuesday, November 18, 2025, at 4:00 p.m. GMT (5:00 p.m. CET).","length":289,"tagName":"p"},{"type":"text","content":"Live webcast and replay: https://wsw.com/webcast/jeff332/medcl/1970687","length":70,"tagName":"p"},{"type":"text","content":"Meetings with the management and with the Business Development team can be requested via direct contact with Medincell or via banking representatives.","length":150,"tagName":"p"},{"type":"text","content":"About Medincell","length":15,"tagName":"p"},{"type":"text","content":"Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.These treatments combine active pharmaceutical ingredients with our proprietary BEPO® technology, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.The first treatment based on BEPO® technology was approved for schizophrenia by the FDA in April 2023 and is now marketed in the Un...